Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: Double tubulin targeting: ORIGINAL ARTICLE

Abstract

Background: Androgen ablation is the standard treatment for advanced prostate cancer. However, most patients will eventually develop progressive hormone-refractory prostate cancer (HRPC). The aim of the Pacl-Vin study was to determine the efficacy and safety of paclitaxel in combination with vinorelbine in patients with HRPC, following from a phase I trial. Methods: Thirty castrate patients with progressive, metastatic prostate cancer were enrolled. Patients were treated with paclitaxel 40 mg/m2, vinorelbine 20 mg/m 2 intravenously on day 1 and day 8 of a 21-day cycle. Results: Two patients demonstrated a partial response and seven patients had stable disease from a cohort of 10 patients wit..